PipelineReview.com2d
Imfinzi-based perioperative regimen approved in the EU for resectable non-small cell lung cancer
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone ...
MPR4d
Imfinzi Combo Therapy Approved for Muscle-Invasive Bladder Cancer
The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...
AstraZeneca’s Imfinzi combination with chemo approved in EU to treat NSCLC
Imfinzi in combination with chemotherapy has been approved in the European Union, EU, for the treatment of adults with ...
Pharmaceutical Technology on MSN5d
FDA approves AstraZeneca’s Imfinzi combo for bladder cancer
The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody Imfinzi (durvalumab) with ...
Fierce Pharma6d
AstraZeneca bulks up Imfinzi's prowess with FDA nod in bladder cancer around surgery
AstraZeneca has secured another expansion of its Imfinzi for use in cancer patients before and after surgery. | Imfinzi is ...
Pharmabiz1d
EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer
EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...
Explore more
European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings
The European Commission on Friday approved AstraZeneca Plc (NASDAQ:AZN) and Daiichi Sankyo's (OTC:DSKNY) Enhertu (trastuzumab ...
Zacks Investment Research on MSN2d
Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure
This week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of ...
Seeking Alpha6d
IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
neoadjuvant chemotherapy alone WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s IMFINZI ® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by ...
CURE4d
Dive Into March 2025 FDA Approvals Across Cancer Subtypes
Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...
Medical Dialogues2d
AstraZeneca Imfinzi-based perioperative regimen approved in EU for resectable non-small cell lung cancer
Cambridge: AstraZeneca has announced that the Company's Imfinzi (durvalumab) in combination with chemotherapy has been ...
Business Wire6d
IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s IMFINZI ® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after ...